ArticleAmerican journal of translational research2026
A clinical study of the CALLY index and HALP score for evaluating response to FOLFOX in colorectal cancer with lung metastases.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the predictive value of the C-reactive protein-albumin-lymphocyte (CALLY) index and the hemoglobin-albumin-lymphocyte-platelet (HALP) score for chemotherapy response and survival outcomes in colorectal cancer (CRC) patients with pulmonary metastases treated with FOLFOX chemotherapy.
methodsThis retrospective study included CRC patients with lung metastases who received first-line FOLFOX-based chemotherapy. Receiver operating characteristic (ROC) curve analysis was used to determine optimal cutoff values for CALLY and HALP in predicting objective response. Logistic regression analyses were performed to identify factors associated with objective response. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox proportional hazards models. Combined risk stratification based on CALLY and HALP was further evaluated.
resultsBoth CALLY and HALP scores were significantly higher in patients achieving objective response than those in non-responders. In multivariable logistic regression, CALLY and HALP were independent protective factors for objective response. Survival analyses demonstrated that low CALLY and low HALP were associated with significantly shorter PFS and OS. In multivariable Cox analyses, HALP remained an independent predictor for both PFS and OS, whereas CALLY was independently associated with PFS and showed a borderline association with OS. Combined stratification based on CALLY and HALP further improved prognostic discrimination. Time-dependent ROC analysis showed that the combined score achieved the highest predictive accuracy at 24 months.
conclusionsCALLY and HALP scores are effective predictors of chemotherapy response and survival in CRC patients with pulmonary metastases receiving FOLFOX. Their combined application enhances risk stratification and may assist in individualized treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.